Modulation of the GITR costimulatory pathway may, therefore, provide a therapeutic strategy for targeting both effector T cells and Tregs in the tumor microenvironment, with the potential to increase T-cell responsiveness against relatively weak antigens, such as those expressed by tumor cells. The gene discussed is TNFRSF18; the disease is neoplasm.